We find where the system broke.
The earliest point the biology went off course.
Disease is a system error. Find it. Fix it.
A conventional symptom approach to disease damage chases what you can see. A system approach follows the wiring.
We fix the break.
The right rewire, the right lever, the right patient, the right dose.
Decode disease damage.
Design new therapies.
Recover viable assets.
What this delivers
Resolve the failure.
Identify the causal failure mechanism and residual biological and clinical viability.
Define the recovery path.
Responder population, therapeutic window, dose, regimen, delivery, combination, metabolites, and endpoint strategy.
Improve portfolio value.
Recover viable assets, terminate non-viable programs earlier, reduce time and capital exposure.
Asset Portfolio Management
Our portfolio intelligence tools combine programmable biology and reverse bioengineering to investigate why Phase I, II, and III assets fail, identify recovery strategies for shelved programs, and strengthen the discovery, design, and development of new assets before costly setbacks occur.
These advanced computational tools connect causal disease-damage modeling with asset intelligence, powered in part by proprietary Human-2-Human (H2H) cryptographic data intelligence, Hybrid AI, autonomous multimodal machine learning loops, virtual research labs, 16-dimensional biological state models, and Digital Quadruplet Perturbation.
LABLOGX
Phase II Failed-Asset Intelligence & Management
BIOALGX is developing a tool to investigate why Phase II drug candidates fail, identify recovery strategies, and assess the conditions required for active Phase I–II assets to succeed. By integrating asset evidence with a systems-level understanding of disease-damage mechanisms, LABLOGX aims to help pharmaceutical partners decide what to advance, what to redesign, what to repurpose, what to combine, and what to stop.
- Advance
- Redesign
- Repurpose
- Combine
- Stop